Blinatumomab

Phase 1Completed

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

B-Cell Acute Lymphoblastic Leukaemia

Conditions

B-Cell Acute Lymphoblastic Leukaemia, ALL, Adult, B-ALL

Trial Timeline

Feb 14, 2020 → Nov 12, 2024

NCT ID

NCT03751709

About Blinatumomab

Blinatumomab is a phase 1 stage product being developed by Amgen for B-Cell Acute Lymphoblastic Leukaemia. The current trial status is completed. This product is registered under clinical trial identifier NCT03751709. Target conditions include B-Cell Acute Lymphoblastic Leukaemia, ALL, Adult, B-ALL.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02187354	Pre-clinical	Completed	—	—	Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia
NCT07192237	Phase 2	Recruiting	Feb 27, 2026	Oct 12, 2032	Phase 2 Study
NCT07134088	Phase 1/2	Recruiting	Dec 8, 2025	Jun 18, 2030	Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
NCT06649006	Phase 1	Completed	Jan 8, 2025	Dec 4, 2025	B-precursor Acute Lymphoblastic Leukemia
NCT06054113	Phase 2	Active	Jul 23, 2024	Oct 14, 2027	B Precursor Acute Lymphoblastic Leukemia
NCT04448834	Phase 2	Withdrawn	Jan 1, 2022	Jun 1, 2023	B-cell Acute Lymphoblastic Leukemia
NCT04506086	Approved	Terminated	Aug 26, 2021	Sep 16, 2024	B-precursor Acute Lymphoblastic Leukemia
NCT04746209	Phase 2	Recruiting	Feb 1, 2021	Dec 31, 2029	B-cell Acute Lymphoblastic Leukemia
NCT04521231	Phase 1/2	Recruiting	Jan 4, 2021	May 25, 2029	B Cell Precursor Acute Lymphoblastic Leukemia
NCT04556084	Phase 2	Terminated	Jan 1, 2021	Oct 1, 2022	B-cell Acute Lymphoblastic Leukemia
NCT04785547	Phase 2	Terminated	Dec 17, 2020	Jan 22, 2022	ALL, Childhood
NCT04044560	Phase 2	Terminated	Sep 8, 2020	Feb 2, 2022	B-cell Adult Acute Lymphoblastic Leukemia
NCT03751709	Phase 1	Completed	Feb 14, 2020	Nov 12, 2024	B-Cell Acute Lymphoblastic Leukaemia
NCT03298412	Phase 2	Terminated	May 23, 2018	Sep 30, 2019	High-risk Diffuse Large B-cell Lymphoma
NCT02961881	Phase 1	Completed	Sep 18, 2017	Sep 2, 2021	Non-Hodgkin's Lymphoma
NCT02910063	Phase 2/3	Completed	Jan 23, 2017	Mar 12, 2020	B-Cell Non Hodgkin Lymphoma
NCT02807883	Phase 2	Completed	Aug 1, 2016	Feb 1, 2022	Acute Lymphoblastic Leukemia
NCT02811679	Phase 2	Terminated	Aug 1, 2016	Dec 1, 2023	Non-Hodgkin Lymphoma
NCT02412306	Phase 1/2	Completed	Jun 4, 2015	Jul 4, 2019	Relapsed Refractory B Precursor Acute Lymphoblastic Leukemia
NCT02000427	Phase 2	Completed	Jan 3, 2014	Jan 6, 2017	Relapsed/Refractory Philadelphia Positive B-precursor ALL

Competing Products

20 competing products in B-Cell Acute Lymphoblastic Leukaemia

See all competitors

Product	Company	Stage	Hype Score
Mitoxantrone hydrochloride liposome Injection-based bridging therapy+ Fludarabine-based chemotherapy +CD19 CAR-T Cells	CSPC Pharmaceutical Group Limited	Phase 2	51
CD19-CAR-T cells	Avalon GloboCare	Phase 1	25
Sepantronium Bromide	Cothera Bioscience	Phase 2	44
rituximab	Celltrion	Phase 1	33
Valemetostat tosylate	Daiichi Sankyo	Phase 2	52
ASP2802 + MA-20	Astellas Pharma	Phase 1	33
ONTAK (denileukin diftitox)	Eisai	Phase 2	52
Tazemetostat	Eisai	Phase 2	52
Tazemetostat	Eisai	Phase 1	33
ME-401	Kyowa Kirin	Phase 1	33
ME-401	Kyowa Kirin	Phase 2	52
LOXO-338 + Pirtobrutinib	Eli Lilly	Phase 1	33
Pirtobrutinib	Eli Lilly	Pre-clinical	23
Rituximab + Gemcitabine	Eli Lilly	Phase 2	52
Ibrutinib	Johnson & Johnson	Approved	85
Ibrutinib 420 mg + Ibrutinib 560 mg	Johnson & Johnson	Approved	85
ACALABRUTINIB + LISOCABTAGENE MARALEUCEL + Lymphodepleting chemotherapy	Johnson & Johnson	Phase 2	52
VELCADE + Rituximab + Cyclophosphamide + Doxorubicin + Prednisone + Vincristine	Johnson & Johnson	Phase 2	52
Ibrutinib	Johnson & Johnson	Pre-clinical	23
SHR1459 tablet + Efavirenz tablet	Jiangsu Hengrui Medicine	Phase 1	33

Other Products from Amgen